• electroCore submitted a 510(k) application to the FDA seeking clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy.
• The submission is supported by two clinical studies involving 168 subjects, including a 142-subject randomized controlled trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854438) on October 28, 2026, and is solely responsible for the information contained therein.